Who are Pliant Therapeutics, Inc.'s main suppliers?

Pliant Therapeutics, Inc. (PLRX) key suppliers include: AstraZeneca PLC, AstraZeneca PLC, Bicara Therapeutics Inc., Bicara Therapeutics Inc., CELG-RI and 11 more. View the full supplier network at chainsifter.com/chain/PLRX.

Who are Pliant Therapeutics, Inc.'s major customers?

Pliant Therapeutics, Inc. (PLRX) key customers include: AstraZeneca PLC, AstraZeneca PLC, Bicara Therapeutics Inc., Bicara Therapeutics Inc., CELG-RI and 9 more. View the full customer network at chainsifter.com/chain/PLRX.

What sector is Pliant Therapeutics, Inc. in?

Pliant Therapeutics, Inc. (PLRX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Pliant Therapeutics, Inc. Suppliers, Customers & Supply Chain (PLRX)

16Suppliers

14Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Pliant Therapeutics, Inc. (PLRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

33Total relationships

4Distinct source URLs

3High confidence

0.730Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Pliant Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate rev…
AZN	AstraZeneca PLC	72%	approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for …
BCAX	Bicara Therapeutics Inc.	72%	Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from BCAX g…
BCAX	Bicara Therapeutics Inc.	72%	duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large scale manufacturing for clinical trials …
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate…
CELG-RI	CELG-RI	72%	approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for …
CRBP	Corbus Pharmaceuticals Holdings, Inc.	72%	Reciprocal relationship from CRBP graph: Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In additi…
CRBP	Corbus Pharmaceuticals Holdings, Inc.	72%	duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large scale manufacturing for clinical trials …
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PLRX graph: health technology assessment. Risks R…
JNJ	Johnson & Johnson	72%	health technology assessment. Risks Related to Our Intellectual Property • Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our p…
MRK	Merck & Co., Inc.	72%	approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for …
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from PLRX graph: approval of our product candidates an…
NKTR	Nektar Therapeutics	72%	health technology assessment. Risks Related to Our Intellectual Property • Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our p…
NKTR	Nektar Therapeutics	72%	Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR g…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from PLRX graph: aring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborati…
NVSEF	Novartis AG	72%	aring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have …

Pliant Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
AZN	AstraZeneca PLC	72%	approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for …
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate rev…
BCAX	Bicara Therapeutics Inc.	72%	duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large scale manufacturing for clinical trials …
BCAX	Bicara Therapeutics Inc.	72%	Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In additi…
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PLRX graph: approval of our product candi…
CELG-RI	CELG-RI	72%	approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for …
CRBP	Corbus Pharmaceuticals Holdings, Inc.	72%	Reciprocal relationship from CRBP graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from PLRX graph: duct candidates and jeopardize our …
CRBP	Corbus Pharmaceuticals Holdings, Inc.	72%	duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large scale manufacturing for clinical trials …
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate rev…
MRK	Merck & Co., Inc.	72%	approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for …
NVSEF	Novartis AG	72%	pearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. …
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NVSE…
ABBVIE-INC-BICARA-THERAPEUTICS-INC-INCYTE-CORPOR	ABBVIE-INC-BICARA-THERAPEUTICS-INC-INCYTE-CORPOR	62%	product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for clinical trials …
BIOMEDICAL-RESEARCH-INC	BIOMEDICAL-RESEARCH-INC	62%	terially from those expressed or implied by forward-looking statements. See "Special Note Regarding Forward-Looking Statements" elsewhere in this Report. RISK FACTORS Risks Related to Our Financial P…

Pliant Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PLRX-DEBT-11805	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.
PLRX-DEBT	Debt stack $28.8M	90%	Market cache reports total debt of $28.8M.

Pliant Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Pliant Therapeutics, Inc..

Pliant Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
PLRX-OWNER-TANG-CAPITAL-MANAGEMENT-LLC	TANG CAPITAL MANAGEMENT LLC	90%	13F overlay lists TANG CAPITAL MANAGEMENT LLC as top holder; 93 tracked holders.

Pliant Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
NKTR	Nektar Therapeutics	100.00	1	['supplier']
BCAX	Bicara Therapeutics Inc.	100.00	1	['customer', 'supplier']
INBX	Inhibrx Biosciences, Inc.	100.00	2
JNJ	Johnson & Johnson	100.00	2	['supplier']
CELG-RI	BRISTOL MYERS SQUIBB CO	100.00	1	['customer', 'supplier']
AZN	AstraZeneca PLC	100.00	2	['customer', 'supplier']
BNTX	BioNTech SE	100.00	2
GNMSF	Genmab A/S	100.00	2
MRK	Merck & Co., Inc.	100.00	1	['customer', 'supplier']
PYXS	Pyxis Oncology, Inc.	100.00	2
NVSEF	Novartis AG	100.00	1	['customer', 'supplier']
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	1	['customer', 'supplier']
GSK	GSK plc	100.00	2
GERN	Geron Corporation	50.00	2
CBIH	Cannabis Bioscience International Holdings, Inc.	50.00	2
EXOZ	eXoZymes, Inc.	50.00	2
CYTK	Cytokinetics, Incorporated	50.00	2
BIOA	BioAge Labs, Inc.	50.00	2
EMMA	Emmaus Life Sciences, Inc.	50.00	2
CTNM	Contineum Therapeutics, Inc.	50.00	2

Pliant Therapeutics, Inc. Supply Chain